S&P 500   3,284.86 (+1.27%)
DOW   28,813.25 (+0.97%)
QQQ   221.83 (+1.71%)
AAPL   317.47 (+2.75%)
FB   218.26 (+1.58%)
MSFT   165.54 (+2.01%)
GOOGL   1,453.45 (+1.52%)
AMZN   1,855.73 (+1.50%)
NVDA   248.65 (+3.52%)
BABA   210.59 (+2.49%)
MU   56.74 (+2.40%)
GE   11.80 (+3.15%)
TSLA   565.05 (+1.26%)
AMD   50.45 (+2.42%)
T   38.72 (+1.23%)
ACB   1.94 (+2.65%)
F   8.99 (+1.01%)
NFLX   351.78 (+2.60%)
BAC   33.37 (+1.58%)
DIS   138.73 (+2.08%)
GILD   64.67 (+1.32%)
S&P 500   3,284.86 (+1.27%)
DOW   28,813.25 (+0.97%)
QQQ   221.83 (+1.71%)
AAPL   317.47 (+2.75%)
FB   218.26 (+1.58%)
MSFT   165.54 (+2.01%)
GOOGL   1,453.45 (+1.52%)
AMZN   1,855.73 (+1.50%)
NVDA   248.65 (+3.52%)
BABA   210.59 (+2.49%)
MU   56.74 (+2.40%)
GE   11.80 (+3.15%)
TSLA   565.05 (+1.26%)
AMD   50.45 (+2.42%)
T   38.72 (+1.23%)
ACB   1.94 (+2.65%)
F   8.99 (+1.01%)
NFLX   351.78 (+2.60%)
BAC   33.37 (+1.58%)
DIS   138.73 (+2.08%)
GILD   64.67 (+1.32%)
S&P 500   3,284.86 (+1.27%)
DOW   28,813.25 (+0.97%)
QQQ   221.83 (+1.71%)
AAPL   317.47 (+2.75%)
FB   218.26 (+1.58%)
MSFT   165.54 (+2.01%)
GOOGL   1,453.45 (+1.52%)
AMZN   1,855.73 (+1.50%)
NVDA   248.65 (+3.52%)
BABA   210.59 (+2.49%)
MU   56.74 (+2.40%)
GE   11.80 (+3.15%)
TSLA   565.05 (+1.26%)
AMD   50.45 (+2.42%)
T   38.72 (+1.23%)
ACB   1.94 (+2.65%)
F   8.99 (+1.01%)
NFLX   351.78 (+2.60%)
BAC   33.37 (+1.58%)
DIS   138.73 (+2.08%)
GILD   64.67 (+1.32%)
S&P 500   3,284.86 (+1.27%)
DOW   28,813.25 (+0.97%)
QQQ   221.83 (+1.71%)
AAPL   317.47 (+2.75%)
FB   218.26 (+1.58%)
MSFT   165.54 (+2.01%)
GOOGL   1,453.45 (+1.52%)
AMZN   1,855.73 (+1.50%)
NVDA   248.65 (+3.52%)
BABA   210.59 (+2.49%)
MU   56.74 (+2.40%)
GE   11.80 (+3.15%)
TSLA   565.05 (+1.26%)
AMD   50.45 (+2.42%)
T   38.72 (+1.23%)
ACB   1.94 (+2.65%)
F   8.99 (+1.01%)
NFLX   351.78 (+2.60%)
BAC   33.37 (+1.58%)
DIS   138.73 (+2.08%)
GILD   64.67 (+1.32%)
Log in

OTCMKTS:PROT - Stromacel Stock Price, Forecast & News

$0.02
-0.01 (-40.00 %)
(As of 01/28/2020 02:42 PM ET)
Today's Range
$0.02
Now: $0.02
$0.02
50-Day Range
$0.01
MA: $0.01
$0.02
52-Week Range
$0.00
Now: $0.02
$0.05
Volume6,500 shs
Average Volume5,833 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PROT
CUSIPN/A
Phone+1-973-5446116

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive PROT News and Ratings via Email

Sign-up to receive the latest news and ratings for PROT and its competitors with MarketBeat's FREE daily newsletter.


Stromacel (OTCMKTS:PROT) Frequently Asked Questions

What is Stromacel's stock symbol?

Stromacel trades on the OTCMKTS under the ticker symbol "PROT."

Has Stromacel been receiving favorable news coverage?

Headlines about PROT stock have trended extremely negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Stromacel earned a news impact score of -5.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Stromacel.

Who are some of Stromacel's key competitors?

Who are Stromacel's key executives?

Stromacel's management team includes the folowing people:
  • Mr. Michael Cohen, Founder, Chairman, CEO, Pres & COO (Age 52)
  • Mr. Steven Byle, CTO & Director (Age 51)
  • Mr. Jason B. Isaacs, Sec. (Age 47)
  • Ms. Jaci Mandil, Chief Exec. Officer of Proteoderm

How do I buy shares of Stromacel?

Shares of PROT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Stromacel's stock price today?

One share of PROT stock can currently be purchased for approximately $0.02.

What is Stromacel's official website?

The official website for Stromacel is http://stromacel.com/.

How can I contact Stromacel?

Stromacel's mailing address is 187 Mill Ln, MOUNTAINSIDE, NJ 07092-2918, United States. The biotechnology company can be reached via phone at +1-973-5446116.


MarketBeat Community Rating for Stromacel (OTCMKTS PROT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  72
MarketBeat's community ratings are surveys of what our community members think about Stromacel and other stocks. Vote "Outperform" if you believe PROT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PROT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Featured Article: Swap

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel